Search

439 results for "lecanemab".

Research summaries 393

Showing the best 200 of 393, 71–80, page 8 of 20. Filter these by subject, year and score in the research library →

1. Lecanemab como tratamiento en el deterioro cognitivo de pacientes con AlzheimerResearch summary

   Research summaries · alzhub.org/study/lecanemab-como-tratamiento-en-el-deterioro-cognitivo-de-pacientes-con-d42e1b7d

   … evaluar el efecto de lecanemab sobre el DC en pacientes con EA.Material y métodos: metaanálisis de artículos originales que evaluaron el DC durante los periodos de intervención con placebo y lecanemab.Resultados: la muestra …

2. Lecanemab in DIAD: 6‐Month Amyloid PET Results from the DIAN‐TU‐001 TrialResearch summary

   Research summaries · alzhub.org/study/lecanemab-in-diad-6month-amyloid-pet-results-from-the-diantu001-trial-41447716

   … anti‐amyloid‐beta antibody lecanemab. Herein, we provide the first results of lecanemab (open‐label) on amyloid PET in a symptomatic DIAD population (the asymptomatic cohort will be evaluated later). Methods The DIAN‐TU‐001 Tau …

3. Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept studyResearch summary

   Research summaries · alzhub.org/study/lecanemab-in-patients-with-early-alzheimer-s-disease-detailed-results-36544184

   Background Lecanemab, a humanized IgG1 monoclonal antibody that targets soluble aggregated Aβ species (protofibrils), has demonstrated robust brain fibrillar amyloid reduction and slowing of clinical decline in early AD. The …

4. Lecanemab preferentially binds to smaller aggregates present at early Alzheimer's diseaseResearch summary

   Research summaries · alzhub.org/study/lecanemab-preferentially-binds-to-smaller-aggregates-present-at-early-40237235

   Introduction The monoclonal antibodies Aducanumab, Lecanemab, Gantenerumab, and Donanemab were developed for the treatment of Alzheimer's disease (AD). Methods We used single-molecule detection and super-resolution imaging to …

5. Lecanemab use for early Alzheimer disease in CanadaResearch summary

   Research summaries · alzhub.org/study/lecanemab-use-for-early-alzheimer-disease-in-canada-42373113

   Lecanemab is a humanized monoclonal antibody that binds soluble brain amyloid-β protein, promoting its removal and slowing the underlying process of Alzheimer disease. 1 This mechanism aligns with the amyloid hypothesis, a …

6. Lecanemab, Donanemab, and Emerging Disease Modifying Therapies for Alzheimer Disease: Clinical Evidence and Primary Care Implications in CanadaResearch summary

   Research summaries · alzhub.org/study/lecanemab-donanemab-and-emerging-disease-modifying-therapies-for-08ace6f7

   Monoclonal antibodies such as lecanemab and donanemab show reduction in amyloid plaque and slowing of cognitive and functional decline (modest) in early AD (mild cognitive impairment or mild dementia). In contrast, Aducanumab …

7. Lecanemab: Wirksamkeit beruht auf dem Fc-Fragment des AntikörpersResearch summary

   Research summaries · alzhub.org/study/lecanemab-wirksamkeit-beruht-auf-dem-fc-fragment-des-antikorpers-0681bd63

   Lecanemab ist eine Anti-Amyloid-Antikörper-Therapie, die entwickelt wurde, um toxische Amyloid-Plaques zu beseitigen und das Fortschreiten der Alzheimer-Krankheit zu verlangsamen. Belgische Forscher*innen versuchten mit Hilfe …

8. Real-world evidence for amyloid-targeted therapies: Lecanemab and donanemabResearch summary

   Research summaries · alzhub.org/study/real-world-evidence-for-amyloid-targeted-therapies-lecanemab-and-42661728

   … in 11.2% (10/89) with lecanemab and 13.3% (11/83) with donanemab-less than in pivotal trials. Modified donanemab titration reduced ARIA versus the original protocol (8.1% vs 28.6%; p = 0.03) and TRAILBLAZER-ALZ 6 (23.6%). No …

9. Transkript zur Episode „Lecanemab“Research summary

   Research summaries · alzhub.org/study/transkript-zur-episode-lecanemab-52ec276c

   … der Markteintritt von Lecanemab und jetzt die Zulassung von Donanemab. Doch was können wir von diesen Alzheimer-Therapien erwarten? Sind sie die Gamechanger oder vielleicht doch nur Hype? Sind sie vielleicht sogar eine Gefahr für …

10. Two cases of Amyloid-Related Imaging Abnormalities (ARIA) following lecanemab treatment for alzheimer's disease and a literature reviewResearch summary

    Research summaries · alzhub.org/study/two-cases-of-amyloid-related-imaging-abnormalities-aria-following-40624486

    … patients treated with lecanemab. Methods We report two clinical cases of ARIA following lecanemab treatment and analyze the imaging features, risk factors, and management strategies of ARIA based on the latest literature. Results …

How this search works

There is no outside search company involved. The site builds its own index by reading its own pages — the same words you would see on the page — and each result shows a literal snippet of that text with your words highlighted. Nothing is summarised or rewritten by a machine in between.

One addition, made by hand: a short list of everyday words that our pages cover under another name. Search "symptoms" and you are also shown The 10 warning signs; "medication" leads to Treatments & medicines; "hotline" to the helplines. A result reached that way shows the page's own description, and it only ever points to a page that already covers the subject.

31503 pages, questions, glossary terms and research summaries are indexed, last rebuilt 2026-11-13. Las páginas en español también aparecen en estos resultados. The clinical trial records are not in this index — they have their own finder, which searches all trial titles, sponsors and drugs directly.